Regulatory Framework for Leadless Cardiac Pacing Systems: Strategic Pathways for FDA Premarket Approval

Read full text Summarise with VIRAT
Authors: Harsh Jitendra Bhai Patel, Aum Prashant Kumar Patel, Peivand Pirouzi
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Leadless cardiac pacing systems represent an innovative evolution in cardiac rhythm management technology, eliminating traditional transvenous leads and subcutaneous generator pockets that have been associated with significant long-term complications. These self-contained pacing units are implanted directly in the cardiac chamber via catheter-based delivery, incorporating pacing electronics, battery, and sensing electrodes in a single miniaturized device. As life-sustaining implantable cardiac devices, leadless pacemakers are classified as Class III medical devices under FDA regulations, requiring Premarket Approval (PMA) with comprehensive clinical evidence demonstrating safety and effectiveness. This article examines the regulatory framework governing leadless pacemaker development, including classification rationale under 21 CFR 870.3610, applicable standards for quality management and risk management, clinical evidence requirements, and strategic considerations for regulatory approval. Project management best practices essential to navigating the complex Class III approval pathway efficiently are discussed. Keywords: leadless pacemaker, cardiac rhythm management, Class III medical device, PMA, FDA, bradycardia, implantable cardiac device, ISO 13485, risk management

Fields of Study & Subjects

Cardiac pacing and defibrillation studies Healthcare Regulation Orthopaedic implants and arthroplasty

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
25 March 2026
Language
EN